Review
Oncology
Miao Liu, Siyao Liu, Liu Yang, Shu Wang
Summary: This study compared the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) and solvent-based taxanes (sb-taxanes) as neoadjuvant therapy in breast cancer treatment, with nab-paclitaxel showing improved pathological complete response rate and event-free survival compared to sb-taxanes.
Review
Oncology
Huaqin Lin, Lei Wang, Xiaohong Zhong, Xueqing Zhang, Lingdong Shao, Junxin Wu
Summary: This meta-analysis comparing neoadjuvant chemotherapy (NAC) and neoadjuvant chemoradiotherapy (NACRT) for locally advanced rectal cancer (LARC) found that NAC was superior to NACRT in terms of sphincter preservation rate, but noninferior in terms of other outcomes. Further validation is needed for these conclusions.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2021)
Article
Pharmacology & Pharmacy
Yue Si, Haiyan Wang, Zijuan Sun, Huijie Shi
Summary: The study aimed to investigate the effect of different medication sequence of taxanes and anthracyclines on the efficacy of neoadjuvant chemotherapy for breast cancer. The use of taxanes followed by anthracyclines or anthracyclines followed by taxanes did not significantly differ in terms of overall survival, disease-free survival, pathological complete response, objective response rate, disease control rate, and breast conservation rate. However, patients in the taxanes -> anthracyclines group were more likely to experience leucopenia as a grade 3-4 adverse reaction compared to the other group. Anthracyclines can be used first and then taxanes for neoadjuvant chemotherapy of breast cancer.
LATIN AMERICAN JOURNAL OF PHARMACY
(2023)
Review
Oncology
Jiuzhou Chen, Yaru Guo, Miao Fang, Yan Yuan, Youqi Zhu, Yong Xin, Longzhen Zhang
Summary: This study evaluated the clinical curative effects and toxicity of neoadjuvant chemoradiotherapy compared to neoadjuvant chemotherapy for resectable gastric cancer. The results showed that neoadjuvant chemoradiotherapy had better efficacy, improved survival rates, and fewer adverse effects compared to neoadjuvant chemotherapy. Therefore, neoadjuvant chemoradiotherapy has great potential as an effective therapy for resectable gastric cancers.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Wei Zhang, Emma Li, Lily Wang, Brian D. D. Lehmann, X. Steven Chen
Summary: This study aimed to identify genes associated with neoadjuvant chemotherapy (NAC) response and disease-free survival (DFS) of triple-negative breast cancer (TNBC) patients. Large-scale meta-analyses were conducted to identify genes associated with NAC response and survival outcomes. The integration and division of gene associations provided insights into potential NAC response mechanisms and biomarker discovery.
Article
Oncology
Jenny Furlanetto, Volker Moebus, Andreas Schneeweiss, Kerstin Rhiem, Hans Tesch, Jens-Uwe Blohmer, Kristina Luebbe, Michael Untch, Christoph Salat, Jens Huober, Peter Klare, Rita Schmutzler, Fergus J. Couch, Bianca Lederer, Bernd Gerber, Dirk-Michael Zahm, Ingo Bauerfeind, Valentina Nekljudova, Claus Hanusch, Christian Jackisch, Theresa Link, Eric Hahnen, Sibylle Loibl, Peter A. Fasching
Summary: The study found that patients with germline BRCA1/2 mutations undergoing standard chemotherapy for early triple-negative breast cancer did not have a higher risk of severe hematological toxicities. However, under treatment with taxanes, patients with BRCA1/2 mutations may have a higher risk of hematological toxicities, suggesting the need for further research.
EUROPEAN JOURNAL OF CANCER
(2021)
Review
Oncology
Ziwei Zhu, Yunyuan Xiao, Shengye Hu, Ziyuan Wang, Zaisheng Zhu
Summary: For patients with variant histology bladder cancers, neoadjuvant chemotherapy (NAC) or adjuvant chemotherapy (AC) can improve overall survival (OS) and cancer-specific survival (CSS) compared with radical cystectomy alone. NAC benefits the sarcomatoid and neuroendocrine subgroups, while only the neuroendocrine subgroup shows improved CSS with AC.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
M. E. Tesch, S. K. Chia, C. E. Simmons, N. LeVasseur
Summary: Data exploring the optimal sequence of anthracyclines and taxanes in neoadjuvant chemotherapy for breast cancer are limited and inconsistent. However, in this real-world analysis, the sequence order did not significantly impact pCR rates or clinical outcomes in HER2-negative breast cancer patients. Triple-negative breast cancer and grade 3 tumors had higher pCR rates.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Review
Oncology
Jinxin Xu, Chun Yan, Zhe Li, Yunpeng Cao, Hongbing Duan, Sunkui Ke
Summary: This study aimed to summarize the efficacy and safety of neoadjuvant chemoimmunotherapy in resectable esophageal squamous cell carcinoma (ESCC). The results showed that neoadjuvant chemoimmunotherapy had a positive impact on improving the pathological response rate and resection rate, with relatively good safety.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Review
Oncology
Jinxin Xu, Chun Yan, Zhe Li, Yunpeng Cao, Hongbing Duan, Sunkui Ke
Summary: This study aimed to summarize the efficacy and safety of neoadjuvant chemoimmunotherapy in resectable esophageal squamous cell carcinoma (ESCC). The meta-analysis results showed that neoadjuvant chemoimmunotherapy is effective and safe for resectable ESCC.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Review
Surgery
Zachary J. Brown, Victor Heh, Hanna E. Labiner, Guy N. Brock, Aslam Ejaz, Mary Dillhoff, Allan Tsung, Timothy M. Pawlik, Jordan M. Cloyd
Summary: Neoadjuvant therapy can increase the surgical resection rates and improve the survival of localized pancreatic cancer patients. The reasons for not undergoing surgery vary depending on the anatomical stage.
BRITISH JOURNAL OF SURGERY
(2022)
Review
Surgery
Qingbin Wu, Jiahao Zhou, Jun Huang, Xiangbing Deng, Changtao Li, Wenjian Meng, Yazhou He, Ziqiang Wang
Summary: This meta-analysis aimed to compare the differences in pathological complete response rate and survival outcomes among patients who received different treatments for rectal cancer. It showed that total neoadjuvant therapy with short-course radiotherapy or long-course chemoradiotherapy improved the pathological complete response rate compared to long-course chemoradiotherapy alone. Total neoadjuvant therapy with long-course chemoradiotherapy and consolidation chemotherapy was associated with better disease-free survival. Both total neoadjuvant therapy with short-course radiotherapy and total neoadjuvant therapy with long-course chemoradiotherapy had similar outcomes in terms of pathological complete response rate and survival.
BRITISH JOURNAL OF SURGERY
(2023)
Review
Oncology
Carolyn Cullinane, Amber Shrestha, Ahmed Al Maksoud, Jane Rothwell, Denis Evoy, James Geraghty, Damian McCartan, Enda W. McDermott, Ruth S. Prichard
Summary: According to the study, the optimal timing for surgery after neoadjuvant chemotherapy for breast cancer is 4-8 weeks post completion. Having surgery within this timeframe is associated with improved overall survival and disease-free survival.
Review
Immunology
Hao Qin, Futao Liu, Yaozhong Zhang, Yuxiang Liang, Yuan Mi, Fan Yu, Haidi Xu, Kuankuan Li, Chenxi Lin, Lei Li, Ziqiang Tian, Lei Wang
Summary: A comprehensive meta-analysis compared the efficacy and safety of neoadjuvant immune checkpoint inhibitor combined with chemotherapy or chemoradiotherapy with routine neoadjuvant strategies in locally advanced esophageal cancer. The results showed that the new immunotherapy approach significantly increased the rates of pathological complete response and major pathological response, with acceptable toxicity. However, larger randomized studies are needed to confirm these findings.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Matthieu Faron, Maurice Cheugoua-Zanetsie, Jayne Tierney, Pierre Thirion, Matthew Nankivell, Kathryn Winter, Hong Yang, Joel Shapiro, Dewi Vernerey, B. Mark Smithers, Thomas Walsh, Guillaume Piessen, Magnus Nilsson, Jurjen Boonstra, Marc Ychou, Simon Law, David Cunningham, Florent de Vathaire, Michael Stahl, Susan Urba, Michele Valmasoni, Daniele Williaume, Janine Thomas, Florian Lordick, Joel Tepper, Jack Roth, Val Gebski, Bryan Burmeister, Xavier Paoletti, Johanna van Sandick, Jianhua Fu, Jean-Pierre Pignon, Michel Ducreux, Stefan Michiels
Summary: This study conducted an individual participant data network meta-analysis to determine the optimal neoadjuvant treatment for resectable carcinoma of the thoracic esophagus or gastroesophageal junction. The results showed that chemotherapy or chemoradiotherapy had better outcomes compared to upfront surgery alone, with variations in treatment effects observed based on tumor location and histology subgroups.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Antonio Brescia, Edoardo Maria Muttillo, Ilaria Angelicone, Isabella Madaffari, Federico Maggi, Isabella Sperduti, Marcello Gasparrini, Mattia Falchetto Osti
Summary: The aim of this study was to evaluate the role of indocyanine green in assessing bowel perfusion, even in cases of low anastomosis on tissue treated with radiotherapy. The results showed that indocyanine green can safely and effectively assess anastomotic perfusion, even in high-risk cases treated with preoperative radiotherapy. However, the lack of a universally replicable standard assessment remains a major limitation.
ANTICANCER RESEARCH
(2022)
Article
Oncology
Stefano Molica, Diana Giannarelli, Mirella Lentini, Daniela Zappala, Ada Mannella, Daniela Loiacono, Valentina Gianfelici, Giuseppina Panduri, Iris Gariani, Pasquale Minchella, Francesco Talarico, Luciano Levato
Summary: The antibody response to the BNT162b2 mRNA COVID-19 vaccine in CLL patients is impaired, with the highest response rate observed in treatment-naive patients and those in sustained clinical remission after therapy. However, CLL patients on certain treatments are less likely to respond well to the vaccine.
Review
Medicine, General & Internal
Luca Mastrantoni, Armando Orlandi, Antonella Palazzo, Giovanna Garufi, Alessandra Fabi, Gennaro Daniele, Diana Giannarelli, Giampaolo Tortora, Emilio Bria
Summary: This systematic review and meta-analysis examined the use of CDK4/6 inhibitors in hormone-receptor positive/HER2-negative metastatic breast cancer. The study found that CDK4/6 inhibitors had a significant benefit in terms of progression-free survival compared to placebo. In terms of adverse events, different CDK4/6 inhibitors had varying advantages and disadvantages. The study confirmed the reliability of LHH as a tool for balancing the risks and benefits of experimental drugs.
Article
Medicine, General & Internal
Silvia Salvatori, Irene Marafini, Martina Franchin, Diletta Lavigna, Mattia Brigida, Chiara Venuto, Livia Biancone, Emma Calabrese, Diana Giannarelli, Giovanni Monteleone
Summary: It has been reported that frailty status can have a negative impact on the clinical progress of patients with inflammatory bowel diseases (IBDs). A recent study found that 20% of IBD patients are frail, and disease activity increases the risk of frailty. The study prospectively monitored a subgroup of frail patients, assessed the reversibility of frailty status, and analyzed factors associated with its reversibility. Results showed that frail phenotype is reversible in most IBD patients, with improvement in disease activity playing a significant role.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Giuditta Chiloiro, Angela Romano, Silvia Mariani, Gabriella Macchia, Diana Giannarelli, Luciana Caravatta, Pierfrancesco Franco, Luca Boldrini, Alessandra Arcelli, Almalina Bacigalupo, Liliana Belgioia, Antonella Fontana, Elisa Meldolesi, Giampaolo Montesi, Rita Marina Niespolo, Elisa Palazzari, Cristina Piva, Vincenzo Valentini, Maria Antonietta Gambacorta
Summary: This study aims to evaluate the role of baseline inflammatory markers as prognostic and predictive factors in a large multicentric Italian cohort of locally advanced rectal cancer patients. The study found that a neutrophil-to-lymphocyte ratio (NLR) >1.2 and a systemic index of inflammation (SII) >500 could predict pathological complete response (pCR). In addition, monocyte-to-lymphocyte ratio (MLR) and hemo-eosinophils inflammation index (HEI) were also associated with disease-free survival (DFS), and age, MLR, and HEI were independent predictors of overall survival (OS).
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY
(2023)
Article
Oncology
Federica Miglietta, Maria Vittoria Dieci, Tommaso Giarratano, Valter Torri, Mario Giuliano, Fable Zustovich, Marta Mion, Carlo Alberto Tondini, Costanza De Rossi, Emilio Bria, Michela Franchi, Laura Merlini, Rosa Giannatiempo, Daniela Russo, Vittoria Fotia, Paola Poletti, Elena Rota Caremoli, Maria Grazia Arpino, Gian Luca De Salvo, Alberto Zambelli, Valentina Guarneri
Summary: This study aims to explore the correlation between RS and TILs in HR+/HER2- breast cancer and propose an immuno-genomic model. The results show that RS and TILs provide slightly overlapping information on the biology of the tumor microenvironment. This finding has implications for guiding the development of immunotherapy strategies for Luminal-like disease.
EUROPEAN JOURNAL OF CANCER
(2023)
Review
Oncology
Inge T. A. Peters, Claudia Marchetti, Antonella De Palma, Diana Giannarelli, Antonella Carcagni, Giovanni Scambia, Anna Fagotti
Summary: First-line maintenance therapy with PARPi significantly improves PFS in patients with advanced high-grade serous and endometrioid EOC. However, the effect of PARPi in relation to postoperative residual disease status is still lacking.
EUROPEAN JOURNAL OF CANCER
(2023)
Review
Health Care Sciences & Services
Marco Sposito, Lorenzo Belluomini, Letizia Pontolillo, Daniela Tregnago, Ilaria Trestini, Jessica Insolda, Alice Avancini, Michele Milella, Emilio Bria, Luisa Carbognin, Sara Pilotto
Summary: Targeted therapy has significantly improved cancer treatment and achieved breakthroughs in various types of cancer. Despite the benefits of adjuvant targeted therapy in some tumors, the optimal duration and management of relapse are still under debate. Neoadjuvant targeted therapy has shown potential value in breast cancer, and ongoing studies are evaluating its use in early-stage NSCLC.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Health Care Sciences & Services
Antonio Franco, Alba Di Leone, Marco Conti, Alessandra Fabi, Luisa Carbognin, Andreina Daniela Terribile, Paolo Belli, Armando Orlandi, Martin Alejandro Sanchez, Francesca Moschella, Elena Jane Mason, Giovanni Cimino, Alessandra De Filippis, Fabio Marazzi, Ida Paris, Giuseppe Visconti, Liliana Barone Adesi, Lorenzo Scardina, Sabatino D'Archi, Marzia Salgarello, Diana Giannarelli, Riccardo Masetti, Gianluca Franceschini, Kenneth P. H. Pritzker
Summary: This study developed a post-Neoadjuvant Score System (pNESSy) to choose the appropriate surgery and improve oncological and aesthetic outcomes. The system uses clinical and radiological features to predict the optimal surgery method post-neoadjuvant chemotherapy.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Oncology
Fabrizio Nelli, Agnese Fabbri, Antonella Virtuoso, Diana Giannarelli, Julio Rodrigo Giron Berrios, Eleonora Marrucci, Cristina Fiore, Marta Schirripa, Carlo Signorelli, Mario Giovanni Chilelli, Francesca Primi, Gloria Pessina, Federica Natoni, Maria Assunta Silvestri, Enzo Maria Ruggeri
Summary: Clinical implications of COVID-19 outbreaks following vaccination in immunocompromised cancer patients were studied. The study found a correlation between antibody levels and the development of breakthrough infections as well as cancer treatment failure. Strategies to enhance antibody levels and prevent virus transmission should be prioritized to mitigate the impact on disease outcomes.
Article
Nursing
Nicolo Panattoni, Isabella Sperduti, Alessandro Spano, Aurora De Leo, Fabrizio Petrone, Emanuele Di Simone
Summary: This study aimed to analyze the principal causes of patients' care calls and compare differences before and after technological modernization of inpatient beds in a surgical breast oncological ward. The findings suggest that the modernization of beds did not lead to effective positive changes, showing an upward trend in care calls.
JOURNAL OF ADVANCED NURSING
(2023)
Article
Oncology
Sara Socorro Faria, Diana Giannarelli, Vladmir Claudio Cordeiro de Lima, Sumadi Luckman Anwar, Chiara Casadei, Ugo De Giorgi, Gabriele Madonna, Paolo Antonio Ascierto, Rossana Veronica Mendoza Lopez, Roger Chammas, Mariaelena Capone
Summary: Breast cancer-related inflammation plays a critical role in tumor development, cancer progression, and patient prognosis. In this study, a prognostic model was established and validated to predict disease-free survival in early-stage breast cancer patients based on readily available baseline clinicopathological prognostic factors and preoperative blood count-derived lymphocyte ratios.
Article
Oncology
Nicolo Bizzarri, Majdi Imterat, Robert Fruscio, Diana Giannarelli, Anna Myriam Perrone, Rosanna Mancari, Alexander Traut, Andrea Rosati, Andreas du Bois, Debora Ferrari, Pierandrea De Iaco, Raffaella Ergasti, Beyhan Ataseven, Tommaso Bianchi, Marco Di Stanislao, Maria Teresa Perri, Florian Heitz, Nicole Concin, Francesco Fanfani, Enrico Vizza, Giovanni Scambia, Philipp Harter, Anna Fagotti
Summary: This study aimed to assess the disease-free survival and overall survival of patients with grade 1-2 endometrioid ovarian carcinoma according to surgical staging. The results showed that lymphadenectomy and younger age were independent protective factors for survival. Patients undergoing lymphadenectomy had better survival rates.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Biochemistry & Molecular Biology
Antonello Vidiri, Simona Marzi, Francesca Piludu, Sonia Lucchese, Vincenzo Dolcetti, Eleonora Polito, Francesco Mazzola, Paolo Marchesi, Elisabetta Merenda, Isabella Sperduti, Raul Pellini, Renato Covello
Summary: The study evaluated the ability of preoperative MRI measurements to predict the pathological T (pT) stage and cervical lymph node metastasis (CLNM) in oral tongue squamous cell carcinoma (OTSCC) using machine learning algorithms. The results showed that MRI measurements were effective in discriminating pT stage and lymph node status, and could be used to predict the outcomes using ML-driven models.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL
(2023)
Article
Oncology
Fabrizio Nelli, Antonella Virtuoso, Diana Giannarelli, Agnese Fabbri, Julio Rodrigo Giron Berrios, Eleonora Marrucci, Cristina Fiore, Enzo Maria Ruggeri
Summary: This study evaluates the impact of concomitant use of acetaminophen (APAP) on the efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer (NSCLC) patients. The findings strengthen the available evidence that concurrent intake of APAP blunts the efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced NSCLC, with the detrimental effects depending on the cumulative dose and duration of exposure to APAP.